Structures by: Wouters J.
Total: 280
C14H8Br2N2O5
C14H8Br2N2O5
CrystEngComm (2015) 17, 12 2523
a=9.188(5)Å b=13.284(7)Å c=14.477(8)Å
α=68.21(5)° β=81.24(4)° γ=75.69(4)°
C17H13NO4
C17H13NO4
CrystEngComm (2015) 17, 12 2523
a=8.4040(5)Å b=11.6930(10)Å c=15.2400(10)Å
α=97.881(6)° β=93.354(5)° γ=96.810(6)°
C15H10N2O5
C15H10N2O5
CrystEngComm (2015) 17, 12 2523
a=3.82890(10)Å b=23.3314(7)Å c=7.4554(2)Å
α=90.00° β=98.153(3)° γ=90.00°
C14H6Br2N2O4
C14H6Br2N2O4
CrystEngComm (2015) 17, 12 2523
a=14.8231(9)Å b=7.7177(6)Å c=25.714(2)Å
α=90.00° β=97.692(7)° γ=90.00°
C14H8Br2N2O5
C14H8Br2N2O5
CrystEngComm (2015) 17, 12 2523
a=14.0897(3)Å b=4.81830(10)Å c=22.6757(3)Å
α=90.00° β=90.607(2)° γ=90.00°
C15H10N2O5
C15H10N2O5
CrystEngComm (2015) 17, 12 2523
a=6.9750(12)Å b=3.8760(10)Å c=23.998(3)Å
α=90.00° β=91.227(12)° γ=90.00°
C8H5NO6,C7H9N
C8H5NO6,C7H9N
CrystEngComm (2015) 17, 12 2523
a=59.519(2)Å b=12.942(5)Å c=7.623(2)Å
α=90.00° β=90.00° γ=90.00°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
C20H28BrF4LiN4O4
C20H28BrF4LiN4O4
CrystEngComm (2013) 15, 44 8898
a=10.1840(10)Å b=24.895(3)Å c=10.777(2)Å
α=90.00° β=90.00° γ=90.00°
C10H18ClF2LiN2O4
C10H18ClF2LiN2O4
CrystEngComm (2013) 15, 44 8898
a=6.197(4)Å b=8.635(2)Å c=28.790(9)Å
α=90.00° β=90.00° γ=90.00°
C22H40LiN4O4,Br
C22H40LiN4O4,Br
CrystEngComm (2013) 15, 44 8898
a=10.408(2)Å b=25.175(3)Å c=10.745(2)Å
α=90.00° β=90.00° γ=90.00°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.3366(4)Å b=6.9013(6)Å c=44.227(4)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
C22H48MgN4O8,2(Cl)
C22H48MgN4O8,2(Cl)
CrystEngComm (2014) 16, 26 5887
a=8.8630(10)Å b=23.742(2)Å c=8.9070(10)Å
α=90.00° β=116.860(10)° γ=90.00°
C20H36F4MgN4O8,2(Cl)
C20H36F4MgN4O8,2(Cl)
CrystEngComm (2014) 16, 26 5887
a=8.850(2)Å b=8.850(2)Å c=34.827(5)Å
α=90.00° β=90.00° γ=120.00°
C11H24Ca1Cl2N2O4
C11H24Ca1Cl2N2O4
CrystEngComm (2014) 16, 26 5887
a=5.9825(11)Å b=9.0582(17)Å c=34.096(6)Å
α=90° β=90° γ=90°
Co-crystals
C10H18CaCl2F2N2O4
CrystEngComm (2014) 16, 26 5887
a=5.9482(8)Å b=9.0116(8)Å c=17.114(2)Å
α=90.00° β=99.350(12)° γ=90.00°
4,10-Dimethoxy-13-(pyridin-3-yl)-6<i>H</i>,12<i>H</i>-6,12-epiminodibenzo[<i>b</i>,<i>f</i>][1,5]dithiocine methanol 0.463-solvate
C21H18N2O2S2,0.463(CH4O)
Acta Crystallographica Section C Structural Chemistry (2020) 76, 3
a=14.7387(4)Å b=16.6445(3)Å c=17.8970(4)Å
α=84.662(2)° β=73.498(2)° γ=68.886(2)°
4-(2-Methoxyphenyl)-4-thiazoline-2-thione
C10H9NOS2
Acta Crystallographica Section C (2016) 72, 5 421-425
a=8.42280(10)Å b=7.90820(10)Å c=16.2102(3)Å
α=90° β=97.152(2)° γ=90°
4-(4-Methoxyphenyl)-4-thiazoline-2-thione
C10H9NOS2
Acta Crystallographica Section C (2016) 72, 5 421-425
a=4.7187(3)Å b=12.0438(7)Å c=17.8972(11)Å
α=90° β=93.752(6)° γ=90°
Clofaziminium hydrogen fumarate
C27H23Cl2N4,C4H3O4
Acta Crystallographica Section B (2019) 75, 4
a=7.47882(9)Å b=26.0041(3)Å c=14.78241(16)Å
α=90° β=102.5075(12)° γ=90°
Clofaziminium hydrogen succinate
C27H23Cl2N4,C4H5O4
Acta Crystallographica Section B (2019) 75, 4
a=10.6376(6)Å b=12.2781(5)Å c=12.7975(8)Å
α=90.079(4)° β=113.211(6)° γ=108.284(4)°
Clofaziminium saccharinate acetonitrile solvate
C27H23Cl2N4,C7H4NO3S,1.393(C2H3N)
Acta Crystallographica Section B (2019) 75, 4
a=7.9970(3)Å b=13.5824(3)Å c=16.6638(7)Å
α=80.214(3)° β=80.034(4)° γ=83.036(3)°
Clofaziminium saccharinate
C34H27Cl2N5O3S
Acta Crystallographica Section B (2019) 75, 4
a=8.2115(7)Å b=13.5327(12)Å c=14.325(3)Å
α=89.040(10)° β=88.864(10)° γ=83.781(7)°
Clofaziminium 2,4-dihydroxybenzoate methanol solvate
C27H23Cl2N4,C7H5O4,C1H4O
Acta Crystallographica Section B (2019) 75, 4
a=9.4861(4)Å b=12.5322(5)Å c=15.3641(5)Å
α=98.415(3)° β=103.379(3)° γ=110.450(4)°
Bis-clofaziminium terephthalate terephthalic acid
C27H23Cl2N4,0.5C8H4O42,0.5C8H6O4
Acta Crystallographica Section B (2019) 75, 4
a=11.7990(4)Å b=12.0736(4)Å c=14.6803(5)Å
α=72.472(3)° β=80.688(3)° γ=72.030(3)°
Bis-clofaziminium terephthalate terephthalic acid
C27H23Cl2N4,0.5C8H4O42,0.5C8H6O4
Acta Crystallographica Section B (2019) 75, 4
a=10.4028(3)Å b=10.8454(3)Å c=15.4229(5)Å
α=71.183(3)° β=73.984(3)° γ=76.148(2)°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.5932(3)Å b=7.8325(3)Å c=11.9547(4)Å
α=90.00° β=103.830(3)° γ=90.00°
C8H14N2O2
C8H14N2O2
Acta Crystallographica Section B (2013) 69, 4 371-378
a=9.3020(8)Å b=11.5223(7)Å c=8.4172(5)Å
α=90.00° β=95.966(7)° γ=90.00°
C8H14N2O2,H2O
C8H14N2O2,H2O
Acta Crystallographica Section B (2013) 69, 4 371-378
a=7.2006(5)Å b=7.9639(5)Å c=9.5468(6)Å
α=85.293(5)° β=76.031(6)° γ=70.023(6)°
C6H10N2O2
C6H10N2O2
Acta Crystallographica Section B (2011) 67, 6 499-507
a=6.5030(10)Å b=6.4180(10)Å c=16.416(3)Å
α=90.00° β=92.087(4)° γ=90.00°
C11H11N2O,Cl,H2O
C11H11N2O,Cl,H2O
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 447-454
a=5.1830(6)Å b=16.808(7)Å c=27.247(3)Å
α=90.00° β=90.00° γ=90.00°
C11H9BrN2O
C11H9BrN2O
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 447-454
a=10.1389(7)Å b=7.5691(5)Å c=27.0498(15)Å
α=90.00° β=90.00° γ=90.00°
C11H9N3O3,3(H2O)
C11H9N3O3,3(H2O)
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 447-454
a=7.0408(3)Å b=8.4596(5)Å c=11.4455(7)Å
α=89.438(5)° β=86.904(4)° γ=82.072(4)°
C11H10BrN2O,Cl,H2O
C11H10BrN2O,Cl,H2O
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 447-454
a=6.845(5)Å b=7.141(5)Å c=13.905(5)Å
α=101.723(5)° β=95.164(5)° γ=100.511(5)°
C11H12N3O3,Cl
C11H12N3O3,Cl
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 447-454
a=21.9100(7)Å b=8.0131(3)Å c=14.3802(4)Å
α=90.00° β=97.325(3)° γ=90.00°
Complex of trimethoprim and fumaric acid
C14H19N4O3,C4H3O4
Acta crystallographica Section B, Structural science, crystal engineering and materials (2015) 71, Pt 4 406-415
a=10.4700(5)Å b=14.6637(10)Å c=15.0285(10)Å
α=61.535(7)° β=83.550(5)° γ=71.020(5)°
11<i>S</i>,13<i>R</i>,16<i>R</i>,18<i>S</i>,22<i>S</i>-1-Azonia-9-ethyl-3- hydroxy-5-(6-methoxy-quinolin-4-yl)-3-methyl- 4-oxatricyclo[6.2.2.0]dodecane trifluoromethanesulfonate
C23H31N2O3,CF3SO3
Acta Crystallographica Section E (2006) 62, 7 o2864-o2865
a=11.3120(10)Å b=8.0590(10)Å c=14.0740(10)Å
α=90.00° β=101.490(10)° γ=90.00°
Cyproterone
C22H27ClO3
Acta Crystallographica Section E (2005) 61, 11 o3576-o3578
a=6.3880(10)Å b=14.182(2)Å c=21.107(3)Å
α=90° β=90° γ=90°
TAPSO
C7H17NO7S
Acta Crystallographica Section C (1996) 52, 7 1684-1686
a=6.689(6)Å b=8.790(9)Å c=9.447(8)Å
α=95.23(9)° β=104.88(7)° γ=92.21(6)°
C8H18N2O4S
C8H18N2O4S
Acta Crystallographica Section C (1996) 52, 7 1687-1688
a=11.804(3)Å b=11.392(3)Å c=16.256(4)Å
α=90.00° β=90.00° γ=90.00°
C11H13NO4
C11H13NO4
Acta Crystallographica Section C (1994) 50, 1 97-100
a=11.546(6)Å b=9.360(2)Å c=4.922(3)Å
α=90.0° β=101.5(2)° γ=90.0°
C12H15NO4
C12H15NO4
Acta Crystallographica Section C (1994) 50, 1 97-100
a=7.295(3)Å b=25.653(5)Å c=6.321(2)Å
α=90.° β=90.° γ=90.°
Oxazolidinone
C3H5NO2
Acta Crystallographica Section C (1997) 53, 7 895-897
a=7.3180(15)Å b=5.6730(11)Å c=9.989(2)Å
α=90.00° β=110.79(3)° γ=90.00°
(5,2'-dithien-2-yl)-2'-deoxyuridine
C17H16N2O5S2
Acta Crystallographica Section C (1997) 53, 7 892-895
a=14.580(2)Å b=18.5345(10)Å c=6.44770(10)Å
α=90.00° β=90.00° γ=90.00°
Lumiflavine
C13H14N6O8
Acta Crystallographica Section C (1995) 51, 6 1223-1227
a=14.0100(10)Å b=7.1040(10)Å c=34.086(2)Å
α=90° β=90° γ=90°
PGlu-Pro-NH~2~
C10H17N3O4
Acta Crystallographica Section C (1997) 53, 4 477-480
a=10.154(2)Å b=8.968(2)Å c=6.749(2)Å
α=90.00° β=104.00(20)° γ=90.00°
2-phenyl-cis-4,6-dimethyl-1,3-diselenane
C12H16Se2
Acta Crystallographica Section C (1998) 54, 10 1505-1507
a=8.582(5)Å b=9.609(5)Å c=31.213(5)Å
α=90.000(5)° β=90.000(5)° γ=90.000(5)°
2:1 complex (N-cyclopentyl-4-phenylpyridinium bromide : 4-phenylpyridine)
2C16H18N1,2Br1,C11H9N1,H1Br1,H2O1
Acta Crystallographica Section C (1996) 52, 4 1033-1036
a=14.692(2)Å b=13.8800(10)Å c=9.7590(10)Å
α=90.00° β=90.00° γ=90.00°
4-Bromo-2H-1,3-Benzoxazine-2,4(1H)-dione
C8H4BrNO3
Acta Crystallographica Section C (1996) 52, 12 3108-3110
a=24.904(5)Å b=6.0290(12)Å c=5.1640(10)Å
α=90.00° β=90.00° γ=90.00°
(+-)-2-Benzoyl-8-ethyl-1,2-dihydroisoquinoline-1-carbonitrile
C19H16N2O
Acta Crystallographica Section E (2007) 63, 7 o3161-o3161
a=7.9960(10)Å b=8.9480(10)Å c=11.297(2)Å
α=108.51(2)° β=94.860(10)° γ=93.040(10)°
Anthraflavic acid
C14H8O4
Acta Crystallographica Section E (2006) 62, 10 o4503-o4505
a=13.640(4)Å b=13.640(4)Å c=6.678(3)Å
α=90.00° β=90.00° γ=90.00°
2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one
C16H13F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=4.918(2)Å b=11.978(6)Å c=24.659(5)Å
α=90.00° β=96.65(2)° γ=90.00°
6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one
C19H11F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=10.3060(10)Å b=10.7980(10)Å c=14.9860(10)Å
α=73.453(6)° β=79.592(7)° γ=89.422(7)°
7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one
C19H11F3N2O2
Acta Crystallographica Section C (2004) 60, 9 o623-o626
a=7.768(2)Å b=8.750(2)Å c=12.703(2)Å
α=89.010(10)° β=81.59(2)° γ=68.050(10)°
{4(S)-(Piperidin-1-ylcarbonyl)-4-[3- (trifluoromethyl)benzenesulfonamido]butyl}guanidinium chloride
C18H27F3N5O3S,Cl
Acta Crystallographica Section C (2006) 62, 12 o691-o693
a=8.3710(10)Å b=9.3510(10)Å c=29.554(3)Å
α=90.00° β=90.00° γ=90.00°
CAROXAZONE
C10H10N2O3
Acta Crystallographica Section C (1994) 50, 11 1774-1777
a=8.0934(10)Å b=19.998(3)Å c=11.926(2)Å
α=90.00° β=90.00° γ=90.00°
P-chlorophenylamidopentanoic acid
C12H14ClNO3
Acta Crystallographica Section C (1994) 50, 1774-1777
a=4.863(5)Å b=9.963(3)Å c=14.024(3)Å
α=69.99(2)° β=76.70(4)° γ=80.28(4)°
(E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine
C16H15ClN4O2
Acta Crystallographica Section C (2005) 61, 9 o531-o532
a=8.2440(10)Å b=8.3190(10)Å c=12.7220(10)Å
α=77.864(7)° β=77.502(6)° γ=66.214(5)°
C12H11N3O2S
C12H11N3O2S
Acta Crystallographica Section C (2002) 58, 2 o69-o71
a=6.2190(10)Å b=12.163(2)Å c=15.8550(10)Å
α=90° β=91.130(10)° γ=90°
C12H13N3O2S
C12H13N3O2S
Acta Crystallographica Section C (2002) 58, 2 o69-o71
a=14.7380(10)Å b=5.7500(10)Å c=15.8980(10)Å
α=90° β=105.020(10)° γ=90°
Lumiflavine
C13H14N6O8
Acta Crystallographica Section C Crystal Structure Communications (1995) 51, 6 1223
a=14.0100(10)Å b=7.1040(10)Å c=34.086(2)Å
α=90° β=90° γ=90°
3-{4-[3(R)-hydroxybutoxy]phenyl}-(R)-5-methoxymethyloxazolidin-2-one
C15H21NO5
Acta Crystallographica Section C (1994) 50, 9 1490-1492
a=9.387(2)Å b=31.005(8)Å c=5.1952(10)Å
α=90° β=90° γ=90°
Terbogrel
C23H27N5O2
Acta Crystallographica Section C (2000) 56, 10 1265-1266
a=14.9340(10)Å b=10.1150(10)Å c=15.7400(10)Å
α=90.00° β=113.049(5)° γ=90.00°
7-nitroindazole
C7H5N3O2
Acta Crystallographica Section C (2000) 56, 10 e474-e475
a=5.0200(10)Å b=9.6360(10)Å c=14.5060(10)Å
α=90.00° β=98.232(4)° γ=90.00°
5-(3,4,5-trimethoxyphenyl)-1,2,3,5,12,12a-hexahydronaphto[1,2-f] indolizine-3,12-dione
C25H23NO5
Acta Crystallographica Section C (2000) 56, 2 193-196
a=10.8680(10)Å b=12.9370(10)Å c=15.0490(10)Å
α=90.00° β=96.009(4)° γ=90.00°
Methyl N-[4-methoxyphenyl-(3,4,5-trimethoxyphenyl)-methyl]pyroglutamate
C23H27NO7
Acta Crystallographica Section C (2000) 56, 2 193-196
a=8.4810(10)Å b=14.2060(10)Å c=18.2730(10)Å
α=90.00° β=90.538(4)° γ=90.00°
5-(3,4,5-trimethoxyphenyl)-1,2,3,5-tetrahydro-11a-naphto[1,8-f,g] indolizine-3-one
C24H23NO4
Acta Crystallographica Section C (2000) 56, 2 193-196
a=9.9090(10)Å b=8.5190(10)Å c=23.7930(10)Å
α=90.00° β=98.104(4)° γ=90.00°
Methyl N-[naphtyl-(3,4,5-trimethoxyphenyl)-methyl]pyroglutamate
C28H30NO8
Acta Crystallographica Section C (2000) 56, 2 193-196
a=9.1900(10)Å b=11.3330(10)Å c=14.7560(10)Å
α=89.292(7)° β=73.923(5)° γ=66.722(7)°
Methyl 4-{cis-2-[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran- 4-yl)phenoxymethyl]-6-hydroxy-3-phenylmorpholino}benzenesulfinate
C30H34FNO7S
Acta Crystallographica Section C (2006) 62, 2 o92-o94
a=7.151(3)Å b=21.430(4)Å c=18.274(3)Å
α=90.00° β=95.479(10)° γ=90.00°
Phenyl 2,3,4-tri-<i>O</i>-benzyl-1-thio-α-D-mannopyranoside monohydrate
C33H34O5S,H2O
Acta Crystallographica Section E (2010) 66, 7 o1525
a=12.6280(10)Å b=8.0840(10)Å c=14.832(2)Å
α=90.00° β=101.380(5)° γ=90.00°
<i>endo</i>-3,3-Dimethyl-4-oxobicyclo[3.1.0]hexan-2-yl methanesulfonate
C9H14O4S
Acta Crystallographica Section E (2010) 66, 4 o948
a=5.8558(3)Å b=7.7497(4)Å c=12.2527(6)Å
α=84.290(4)° β=79.531(4)° γ=72.070(5)°
Dicyclohexylaminium (<i>S</i>)-2-(1,3-dioxoisoindolin-2-yl)-3-(1<i>H</i>-indol-3-yl)propanoate dimethylformamide solvate monohydrate
C12H24N,C19H13N2O4,C3H7NO,H2O
Acta Crystallographica Section E (2010) 66, 12 o3175-o3176
a=9.08840(10)Å b=15.0206(3)Å c=24.4749(5)Å
α=90.00° β=90.00° γ=90.00°
IB07
C19H13N3O6
Acta Crystallographica Section E (2011) 67, 8 o2116
a=7.0569(3)Å b=15.5302(8)Å c=7.6947(4)Å
α=90.00° β=95.415(4)° γ=90.00°
C8H14N2O2,C6H10O4
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=12.9082(9)Å b=11.5417(8)Å c=12.5179(9)Å
α=90.00° β=116.342(9)° γ=90.00°
Levetiracetam 2,2-dimethylsuccinic acid cocrystal
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.23877(7)Å b=11.55362(12)Å c=11.34360(12)Å
α=90.00000° β=90.9259(9)° γ=90.00000°
Etiracetam 2,4-dihydroxybenzoic acid cocrystal
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.60584(3)Å b=13.11919(7)Å c=18.80723(8)Å
α=90.00000° β=90.00000° γ=90.00000°
C8H14N2O2,C7H5NO4
C8H14N2O2,C7H5NO4
Crystal Growth & Design (2014) 14, 6 2880
a=5.8455(2)Å b=11.6845(12)Å c=12.5762(10)Å
α=78.856(8)° β=82.443(6)° γ=84.035(7)°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=8.0511(4)Å b=13.0536(6)Å c=23.0243(9)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=24.2697(8)Å b=7.4683(2)Å c=13.3230(5)Å
α=90.00° β=104.663(4)° γ=90.00°
2(C7H5NO4),C8H14N2O2
2(C7H5NO4),C8H14N2O2
Crystal Growth & Design (2014) 14, 6 2880
a=7.0988(9)Å b=7.3613(10)Å c=12.1428(13)Å
α=77.496(10)° β=88.250(10)° γ=74.232(12)°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7253(2)Å b=20.2528(7)Å c=10.9457(5)Å
α=90.00° β=100.085(4)° γ=90.00°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7646(4)Å b=19.8963(14)Å c=11.0690(8)Å
α=90.00° β=99.331(6)° γ=90.00°
Stanozolol / malonic acid cocrystal
C21H32N2O,C3H4O4
Crystal Growth & Design (2014) 14, 7 3408
a=10.6644(7)Å b=7.2335(5)Å c=15.0947(10)Å
α=90.00° β=106.016(7)° γ=90.00°
Stanozolol / D-phenyllactic acid cocrystal
2(C21H32N2O),C9H10O3,C2H3N
Crystal Growth & Design (2014) 14, 7 3408
a=58.6098(12)Å b=7.5624(2)Å c=10.7139(4)Å
α=90.00° β=97.989(2)° γ=90.00°
Stanozolol / 6-hydroxy-2-naphthoic acid
C21H32N2O,C11H8O3
Crystal Growth & Design (2014) 14, 7 3408
a=7.9530(6)Å b=8.6403(7)Å c=10.4582(7)Å
α=83.337(6)° β=86.973(6)° γ=75.431(7)°
2(C10H16N2O2),C4H6O6
2(C10H16N2O2),C4H6O6
Crystal Growth & Design (2014) 14, 8 3996
a=10.7203(7)Å b=9.3534(4)Å c=14.3581(11)Å
α=90.00° β=110.236(8)° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=12.0408(8)Å b=5.9067(3)Å c=12.1169(8)Å
α=90.00° β=113.961(8)° γ=90.00°
C8H14N2O2,C5H8O4
C8H14N2O2,C5H8O4
Crystal Growth & Design (2014) 14, 8 3996
a=5.9628(4)Å b=11.5797(8)Å c=22.5983(18)Å
α=90° β=95.615(8)° γ=90°
C13H18O2,C8H14N2O2
C13H18O2,C8H14N2O2
Crystal Growth & Design (2014) 14, 8 3996
a=7.351(2)Å b=9.780(3)Å c=29.993(5)Å
α=90.00° β=90.00° γ=90.00°
C9H7NS2
C9H7NS2
Crystal Growth & Design (2015) 15, 5 2461
a=34.675(3)Å b=34.675(3)Å c=4.0950(4)Å
α=90.00° β=90.00° γ=120.00°
C33 Polymorph I
C9H7NS2
Crystal Growth & Design (2015) 15, 5 2461
a=6.2423(2)Å b=11.5747(3)Å c=12.7785(4)Å
α=90.00° β=101.780(3)° γ=90.00°
C15H13FN2O
C15H13FN2O
Crystal Growth & Design (2015) 15, 8 4005
a=20.3160(18)Å b=5.2050(3)Å c=13.5364(14)Å
α=90.00° β=114.387(12)° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2015) 15, 8 4005
a=18.549(3)Å b=13.827(2)Å c=5.3162(7)Å
α=90.00° β=90.00° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2015) 15, 8 4005
a=7.0276(4)Å b=7.7445(5)Å c=25.6078(13)Å
α=90.00° β=90.00° γ=90.00°
C16H16N2O
C16H16N2O
Crystal Growth & Design (2015) 15, 8 4005
a=8.2225(4)Å b=5.7932(3)Å c=14.5687(6)Å
α=90.00° β=90.377(4)° γ=90.00°